Anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones as a New Class of Antistaphylococcal Agents: Synthesis and biological evaluation

Article abstract of DOI:10.3390/molecules24244581

The development and spread of resistance of human pathogenic bacteria to the action of commonly used antibacterial drugs is one of the key problems in modern medicine. One of the especially dangerous and easily developing antibiotic resistant bacterial species is Staphylococcus aureus. Anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones 22–38 have been developed as novel effective antistaphylococcal agents. These compounds have been obtained by sequential conversion of 1-amino-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid (1) and 1-amino-4-bromo-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid (2) into the corresponding amides 5–21, followed by subsequent endo-cyclization under the influence of sodium nitrite in acetic acid. Evaluation of the antimicrobial activity of the synthesized compounds against selected species of Gram-positive and Gram-negative bacteria as well as pathogenic yeasts of the Candida genus has been carried out by the serial dilution method. It has been established that anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones exhibit selective antibacterial activity against Gram-positive bacteria. Eight, six and seven, out of seventeen compounds tested, effectively inhibited the growth of S. aureus ATCC 25923, S. aureus ATCC 29213 and S. epidermidis ATCC12228, respectively, at a concentration equal to 1 μg/mL or lower. The high antistaphylococcal potential of the most active compounds has been also confirmed against clinical isolates of S. aureus, including the MRSA strains. However, bacteria of the Staphylococcus genus have demonstrated apparent resistance to the novel compounds when grown as a biofilm. None of the four selected compounds 3234 and 36 at a concentration of 64 μg/mL (128 or 256 × MIC—against planktonic cells) has caused any decrease in the metabolic activity of the staphylococcal cells forming the biofilm. The kinetic time–kill assay revealed some important differences in the activity of these substances. Compound 33 is bacteriostatic, while the other three demonstrate bactericidal activity.

Full text of DOI:10.3390/molecules24244581

AArtniclethra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones
as a New Class of Antistaphylococcal Agents:
Synthesis and Biological Evaluation
1
1,
1
2
Viktor Zvarych , Maryna Stasevych *, Volodymyr Novikov , Eduard Rusanov ,
2
3
3
3
Mykhailo Vovk , Piotr Szweda , Katarzyna Grecka and Slawomir Milewski
1
Department of Technology of Biologically Active Substances, Pharmacy and Biotechnology, Lviv
Politechnic National University, 13, 79013 Lviv, Ukraine; viktor.i.zvarych@gmail.com (V.Z.);
vladnovikov@list.ru (V.N.)
Department of Mechanism of Organic Reactions, Institute of Organic Chemistry of National Academy of
Sciences of Ukraine, 02660 Kyiv, Ukraine; rusanov@ioch.kiev.ua (E.R.); mvovk@ioch.kiev.ua (M.V.)
Department of Pharmaceutical Technology and Biochemistry, Gdańsk University of Technology,
80-233 Gdańsk, Poland; piotr.szweda@wp.pl (P.S.); kagrecka@gmail.com (K.G.);
slawomir.milewski@pg.edu.pl (S.M.)
2
3
* Correspondence: maryna.v.stasevych@gmail.com; Tel.: +38-032-258-22-09
Received: 20 November 2019; Accepted: 12 December 2019; Published: 13 December 2019
Abstract: The development and spread of resistance of human pathogenic bacteria to the action of
commonly used antibacterial drugs is one of the key problems in modern medicine. One of the
especially dangerous and easily developing antibiotic resistant bacterial species is Staphylococcus
aureus. Anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones 22–38 have been developed as novel effective
antistaphylococcal agents. These compounds have been obtained by sequential conversion of 1-
amino-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid (1) and 1-amino-4-bromo-9,10-dioxo-
9,10-dihydroanthracene-2-carboxylic acid (2) into the corresponding amides 5–21, followed by
subsequent endo-cyclization under the influence of sodium nitrite in acetic acid. Evaluation of the
antimicrobial activity of the synthesized compounds against selected species of Gram-positive and
Gram-negative bacteria as well as pathogenic yeasts of the Candida genus has been carried out by
the serial dilution method. It has been established that anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones
exhibit selective antibacterial activity against Gram-positive bacteria. Eight, six and seven, out of
seventeen compounds tested, effectively inhibited the growth of S. aureus ATCC 25923, S. aureus
ATCC 29213 and S. epidermidis ATCC12228, respectively, at a concentration equal to 1 µg/mL or
lower. The high antistaphylococcal potential of the most active compounds has been also confirmed
against clinical isolates of S. aureus, including the MRSA strains. However, bacteria of the
Staphylococcus genus have demonstrated apparent resistance to the novel compounds when grown
as a biofilm. None of the four selected compounds 3234 and 36 at a concentration of 64 µg/mL (128
or 256 × MIC—against planktonic cells) has caused any decrease in the metabolic activity of the
staphylococcal cells forming the biofilm. The kinetic time–kill assay revealed some important
differences in the activity of these substances. Compound 33 is bacteriostatic, while the other three
demonstrate bactericidal activity.
Keywords: anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones; anti-Staphylococcus aureus agents;
antibacterial study
1. Introduction
The resistance of human pathogenic bacteria and yeasts to the well-known antibiotics and
synthetic chemotherapeutics is becoming a major global health challenge [1–3]. Among the array of
Molecules 2019, 24, 4581; doi:10.3390/molecules24244581
www.mdpi.com/journal/molecules

Molecules 2019, 24, 4581
2 of 20
various antibiotic-resistant pathogenic bacteria, staphylococci belong to the most common and
dangerous. They are able to produce a wide array of virulence factors and have evolved mechanisms
of resistance to a plethora of antibiotics currently in use for human and animal therapies. As a
consequence, bacteria of the Staphylococcus genus, particularly S. aureus, are responsible for a broad
spectrum of difficult to treat diseases including skin and ocular infections, foodborne illness,
pneumonia, meningitis, endocarditis, and osteomyelitis [4]. Over the past decades, this bacterium
has become the main cause of bloodstream infections (BSI) in the world, with a mortality level of 20–
40% [5]. Recent advances in the developments of antistaphylococcal agents are presented in works
on search of new non-antibiotic agents: peptidoglycan hydrolases compounds of plant origin (plant
extracts, essential oils and their components) [6–9], vaccines development [8], silver nanoparticles
[10], bacteriocins [11], and bacteriophages [12]. Currently, the most reasonable approach for
understanding the crucial cellular pathways by which unknown to date (or not used as antimicrobial
agents) molecules affect pathogenic microorganisms at a molecular level seems to be transcriptome
analysis. Recently, Chauhan and coworkers [13] successfully applied RNA sequencing for the
determination of antistaphylococcal modes of action of novel discovered benzimidazole molecules.
Comparative analysis of differentially expressed genes between control and treated S. aureus cells
showed selective hits. Therefore, the search and development for new antibacterial agents effective
against these pathogenic bacteria remain an urgent task of the present.
Derivatives of the 9,10-anthraquinone of both natural and synthetic origin are well known for
their wide range of biological effects. Of particular interest, compounds with an antibacterial effect
are known among them [14–17]. The 1,2,3-triazinone ring is an important biophore fragment for the
creation of new promising antimicrobial agents based on the 9,10-anthraquinone platform. This
pharmacophore is a structural component of many natural and synthetic biologically active
compounds with various therapeutic effects [18,19]. The compounds with a sedative, diuretic,
anesthetic, antiarthritic, antitumor, antibacterial, antifungal, antituberculosis, antiviral,
antiinflammatory, antihistamine activity were found among 1,2,3-triazine derivatives connected with
various carbo- and heterocyclic fragments [20–23].
It is known that diazotization of the corresponding ortho-amino amides with NaNO2 or t-
BuONO under slightly acidic conditions is one of the most common methods for the formation of the
1,2,3-triazin-4-one ring [15]. Despite the widespread use of this method, condensed carbocyclic 1,2,3-
triazin-4-one derivatives are known only for the benzene and naphthalene systems [24]. In the context
of the above, herein we report a method for the synthesis of new triazine-containing anthraquinone
structures and the study their antibacterial effect for identifying potential antimicrobial agents.
2. Results and Discussion
2.1. Chemistry
Continuing our research on the directed functionalization of the 9,10-anthraquinone system and
the search for new biologically active substances [25–30], in the work presented herein we report an
effective synthetic approach to a number of new condensed anthraquinone derivatives, namely
anthra [1,2-d][1,2,3]triazine-4,7,12(3H)-triones 22–38 (Scheme 1).
Commercially available 1-amino-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid (1) and 1-
amino-4-bromo-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid (2) were converted into the
corresponding acid chlorides 3 and 4 by treatment with thionyl chloride in the presence of a catalytic
amount of pyridine. The amides 5–21 were prepared from acid chlorides 3 and 4 and ammonia,
cyclohexylamine and a variety of anilines (Scheme 1).
The target compounds 22–38 were synthesized via an intramolecular cyclization reaction of
amides 5–21 with nitrous acid generated in situ in acetic acid at room temperature in 63–90% yields
(Scheme 2). It should be noted that the use of t-BuONO as a diazotizing agent in the reactions at 20–
65 °C proved to be ineffective and gave a low conversion of amides 5–21. Moreover, the presence of
a bromine atom at the position 4 of the anthracenedione ring did not provide for a significant impact
on the cyclization process.

Molecules 2019, 24, 4581
3 of 20
Scheme 1. Synthesis of amides 5–21. Reagents and conditions: (i) thionyl chloride (3 eguiv), pyridine (0.15 equiv), dry benzene, 80 °C, 5 h, (ii) for compounds 5 and 14—
25% NH4OH (50 mL), −15 °C, 1 h → 80 °C, 3 h → r.t., 10% HCl; for compounds 6–13, 15–21—R1NH2 (1.1 equiv), dry benzene, TEA (1.1 equiv), ∆, 12 h.

Molecules 2019, 24, 4581
4 of 20
Scheme 2. Synthesis of anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones 22–38.

Molecules 2019, 24, 4581
5 of 20
The formation of amides 6,7,9,10,15,16,18 was confirmed by the presence of a broad singlet of
1
proton of the NH group of the amide fragment in the range of 10.03–10.72 ppm in the H-NMR
spectra. Also, the signal of protons of the NH group falls into the region of aromatic anthracenedione
2
and benzene protons. The amide protons in N-cyclohexyl-substituted amides 8 and 17 resonated in
the aromatic proton region of the quinoid ring.
The carbon atom signal of the carbonyl group of amide residue of 5–21 was observed within the
13
range of 165.25–169.76 ppm in the C-NMR spectra. In the case of fluorine-containing amides
9,10,15,18, the characteristic doublet signals attributable to the C-F bond in the meta or para position
of the benzene residue were presented in the range from 158.19 to 163.45 ppm with a coupling
constant of J = 241.1 Hz.
The characteristic broad singlet signal of NH proton at 15.37 and 15.45 ppm was presented in
1
13
the H-NMR spectra of anthratriazinones 22 and 31. In the C-NMR spectra of compounds 22,31, the
signal of the carbon atom of the carbonyl group in the triazine ring was shifted by 16 ppm compared
to the C=O group in the corresponding amides 5 and 14. Additionally, the structure of anthra[1,2-
d][1,2,3]triazine-4,7,12(3H)-trione 22 was confirmed by X-ray diffraction analysis (Figure 1).
Figure 1. Molecular structure of 22. Ellipsoids are drawn at 50% probability level (CCDC 1966785).
In structure of compound 22 (Figure 2) the central tetracyclic system is strongly conjugated and
planar (Rms deviation of fitted atoms 0.0399), while the atoms O
2
and O deviate out of this plane for
3
0.200(3) and 0.154(3) Å respectively. In crystal molecules packed in columns directed along a
crystallographic axis.
Figure 2. Molecular packing of 22 (viewed along the a crystallographic axis).

Molecules 2019, 24, 4581
6 of 20
The shortest intermolecular distances between neighboring molecules in columns are 3.342 Å
and 3.424 Å for C···N and C···C contacts correspondingly, thus π-π stacking in columns is observed.
Solvate water molecules occupy volume between the columns and bonding together neighboring
columns by the system of hydrogen bonds. The parameters of H-bonds in a crystal are shown in Table
1. The combination of π-π stacking in columns along axes a and 2D hydrogen bonds across b and c
3
direction giving 3D net and densely packed crystal with density 1.59 g/cm .
Table 1. Parameters of hydrogen bonds in crystal of compound 22.
D-H ···A
N3-H3···O4
O4-H41··· O1_$1 *
O4-H42 ···O2_$2 *
O4-H42 ···N1_$2 *
D-H(Å)
1.01(3)
0.92(5)
0.91(5)
0.91(5)
D···A(Å)
2.732(3)
2.844(3)
2.867(4)
3.097(3)
D-H-A(°)
175 (3)
166 (4)
142 (3)
143 (3)
* The atoms marked by symbol $1 and $2 are connected to base atoms by symmetry operations 1 − x,
3 − y, −z and 1 − x, y + 0.5, −z − 0.5, respectively.
2.2. Biological Studies
2.2.1. Determination of MIC Values of Synthesized Agents against Reference Strains of Bacteria and
Yeasts and Clinical Isolates of S. aureus
The outcomes of our investigation revealed that synthesized anthra[1,2-d][1,2,3]triazine-
4,7,12(3H)-triones exhibited selective antibacterial activity against staphylococci (Table 2). Eight, six
and seven out of seventeenths compounds tested inhibited the growth of S. aureus ATCC 25923, S.
aureus ATCC 29,213 and S. epidermidis respectively at a concentration equal to 1 µg/mL or lower. This
level of activity is comparable to the activity of many antibacterial antibiotics (Table 2) [7,31,32]. The
tested antibiotics exhibited activity with the range of MIC from 0.125 to 16.0 µg/mL in the case of
staphylococci.
Up to the concentration of 32 µg/mL, no activity was observed against both investigated
reference strains of Gram-negative bacteria, namely E. coli ATCC 25,922 and P. aeruginosa ATCC
27,853 nor the human pathogenic yeasts of the Candida genus. Our research revealed also lower
activity of investigated antibiotics against Gram-negative bacteria. Six out of seven tested antibiotics
did not affect E. coli and P. aeruginosa up to the highest tested concentration—32.0 µg/mL. The high
antistaphylococcal potential of selected agents was additionally confirmed against clinical isolates of
S. aureus. Interestingly, no difference was observed in the susceptibility of MRSA and MSSA strains
(Table 3), which is very important from the clinical point of view. Five of these substances inhibited
the growth of all strains tested at the concentration not higher than 1 µg/mL. The four most active
compounds, namely 32–34, and 36 were selected for further tests.
Several research groups also synthesized heterocyclic compounds of similar structures.
However, according to our best knowledge, none of those compounds exhibited comparable
antistaphylococcal activity (MIC values below 1 µg/mL) [33–36]. Moreover, the results presented by
other authors did not indicate similar selectivity of antimicrobial properties (high activity against
Gram-positive bacteria and no activity against both Gram-negative bacteria and human pathogenic
yeasts) [33–35]. In some cases, it is difficult to compare results, because different method of
determination of antimicrobial activity (disc diffusion) was used by the authors [33,34].

Molecules 2019, 24, 4581
7 of 20
Table 2. Antimicrobial activity (MIC, µg/mL) of synthesized anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones and randomly selected antibiotics.
Pathogen
Agent
S. aureus ATCC
S. aureus ATCC
S. epidermidis ATCC
E. coli ATCC
25922
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
2.0
P. aeruginosa ATCC C. albicans ATCC
C. albicans SC
5314
C. glabrata
DSM11226
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
ND
C. krusei
25923
4.0
2.0
0.5
4.0
2.0
4.0
1.0
2.0
2.0
8.0
0.25
0.25
0.25
4.0
0.25
0.5
29213
4.0
2.0
0.5
8.0
4.0
8.0
2.0
16.0
2.0
4.0
0.25
0.25
0.5
8.0
0.5
1.0
2.0
12228
8.0
1.0
0.5
8.0
2.0
8.0
2.0
2.0
2.0
8.0
0.125
0.25
0.25
8.0
0.125
0.125
2.0
27853
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
2.0
10231
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
ND
DSM6128
>32.0
>32.0
32.0
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
ND
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
32.0
ND
ND
ND
ND
ND
ND
ND
38
1.0
Ampicillin
Gentamicin
Fusidic acid
Linezolid
Daptomycin
Oxacillin
Levofloxacin
0.25
0.125
0.5
2.0
1.0
8.0
0.5
0.25
1.0
1.0
16
0.5
0.125
1.0
2.0
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
>32.0
ND
ND
ND
ND
0.25
0.125
0.125
0.25
0.125
0.125
ND
Eight substances selected for investigation of their activity against clinical isolates are marked with a gray background and four compounds with the highest activity that
were selected for further study (kill-time assay, antibiofilm activity, and influence on enzyme activity) are underlined and bolded. ND—not determined.

Molecules 2019, 24, 4581
8 of 20
Table 3. Antimicrobial activity (MIC, µg/mL) of eight selected compounds against clinical isolates of
S. aureus (MSSA and MRSA).
Pathogens—Clinical Isolates of S. aureus
Agent
1
2
3
4
5
6
7
8
MRSA1 MRSA2 MRSA3 MRSA4
23
24
26
32
33
34
36
37
4.0
1.0
2.0
8.0
1.0
2.0
4.0
8.0
8.0
8.0
8.0
0.5
1.0
8.0
0.5
2.0
8.0
1.0
4.0
0.25
0.5
0.5
0.5
1.0
2.0
1.0
2.0
0.25
0.5
0.125
1.0
8.0
0.5
1.0
0.25
0.25
0.25
0.25
1.0
8.0
0.5
2.0
0.25
0.5
0.25
0.5
0.5 0.25 0.25 1.0
1.0 1.0 1.0 4.0
0.25 0.25 0.25 0.25 0.25 0.5 0.25 0.125
0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
0.25 0.5 0.25 0.25 0.5 0.25 0.25 0.25
0.25 0.5 0.25 0.5
0.5 0.5 0.5 1.0
1.0
1.0
0.5 0.25
0.5 1.0
0.5
0.5
1.0
2.0
2.2.2. Bactericidal Effect of Selected Compounds
The structures of four compounds selected for further analysis, namely 32, 33, 34 and 36, are
similar. Despite this fact, the kinetic time—kill assay revealed some important differences in the
activity of these substances. The respective curves are shown in Figure 3. Compound 33 was
apparently bacteriostatic only and did not exhibit any bactericidal effect, while the other three
demonstrated a clear such effect, i.e., their action resulted in some reduction of the cell number, even
in the case of its concentrations 2 or 4 times higher than MIC. Undoubtedly, compound 34 was the
most effective in this respect. A substantial reduction of the log10 CFU value (from 6 to 0) of the
bacterial cell suspension was observed at 4 × MIC after 1 h-long treatment with this compound and
at 2 × MIC after 3 h-long treatment. In the case of compound 36, such reduction of the cell number
was achieved only at 4 × MIC after 1 h-long treatment. The action of compound 32 resulted in a
maximal reduction of log10 CFU from 6 to 2 after 6 h-long treatment at 4 × MIC. Therefore, the
bactericidal potential of compounds tested ranks them in the 34 > 36 > 32 order, whereas compound
33 was not bactericidal at all. For all four compounds, the re-growth of bacterial cells was observed
after 24 h-long treatment. This observation indicates that even in the cases when the reduction of log10
CFU from 6 to 0 was noted after shorter treatments, some residual live cells must have been
preserved.

Molecules 2019, 24, 4581
9 of 20
Figure 3. Results of the kinetic time—kill assay for compounds 32–34 and 36.
2.2.3. Activity of the Selected Compounds against Staphylococcal Biofilm
When the S. aureus cells were grown in the biofilm mode, the antistaphylococcal potential of
compounds 32–34 and 36 appeared much lower, if any, than that found against the cells grown in the
planktonic mode. None of these compounds caused any decrease in the metabolic activity of the cells
forming the biofilm, as measured with the MTT assay, at concentrations as high as 64 µg/mL (128 or
256 × MIC). It is not especially surprising, since many earlier reports indicated that for different
antibacterial agents, their effective concentrations inhibiting metabolic activity of staphylococci
grown in the biofilm mode can be 10–1000 times higher than those inhibiting the planktonic growth
[37]. This is because the embedded bacterial cells are getting an optimal defense mechanism against
the adverse effects of antibiotics and the immune system of the host [37]. Thus in our opinion, the
evidentially lower activity against biofilm should not be considered as a crucial disadvantage of the
synthesized compounds.
2.2.4. Influence of the Selected Compounds on Metabolic Activity
When a semi-quantitative API ZYM micro-method was applied for the determination of
influence of the selected compounds on activity of 19 hydrolases of S. aureus, it appeared that the S.
aureus ATCC 29,213 reference strain exhibited activity of 5 enzymes, namely alkaline phosphatase,
esterase (C4), esterase lipase (C8), acid phosphatase and naphthol-AS-BI-phosphohydrolase.
Analysis of the enzymatic activity of bacterial cells treated with the selected agents at ½ × MIC, results
of which are shown in Table 4, revealed a statistically significant decrease in the activity of alkaline
phosphatase, esterase (C4) and esterase lipase (C8). The activity of two other enzymes was not
affected.
Table 4. Influence of selected compounds on enzymatic activity of S. aureus ATCC 29,213.
Enzyme
Compound
Alkaline
Esterase
Esterase
Acid
Naphthol-AS-BI-
phosphatase
(C4)
Lipase (C8)
Phosphatase
Phosphohydrolase
Control
32
5
4
3
3
4
5
5
4
3
2
5
4
4
4
4
5
5
5
5
5
5
5
5
5
5
33
34
36
In order to explain whether the observed reduction of activity of some enzymes could be a
consequence of the killing of bacterial cells, the determination of CFU number in treated and control
samples was performed. No difference was observed (no killing effect in the presence of the agents
at a concentration of ½ MIC during 1 h incubation was observed). It clearly indicates that treatment
of the cells with the selected substances (at a concentration lower than MIC) importantly affected the
activity of some of the important enzymes, however without any lethal effect.

Molecules 2019, 24, 4581
10 of 20
Therefore, the outcomes of our biological investigation revealed the very high
antistaphylococcal activity against S. aureus ATCC 25923, S. aureus ATCC 29,213 and S. epidermidis
ATCC12228 of some synthesized anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones at the concentration of
0.125–0.5 µg/mL, while randomly selected antibiotics have MIC in the range of 0.125–8.0 µg/mL. The
high antistaphylococcal potential of the most active compounds, namely 32–34 and 36, has been also
confirmed against clinical isolates of S. aureus, including the MRSA strains. The obtained results
create the prospect of their further in-depth studies as effective antibacterial agents.
3. Materials and Methods
3.1. General Information
Melting points were measured in open to air glass capillaries using a B-540 melting point
apparatus (Büchi, New Castle, DE, USA) and are uncorrected. Elemental analysis was performed on
a 2400 CHN-analyzer (PerkinElmer, Wilmington, DE, USA) and the results were found to be in good
1
13
agreement with the calculated values. H-NMR spectra (400 MHz) and C-NMR spectra (100 MHz)
were recorded in DMSO-d6 (unless otherwise indicated) on a Mercury-400 spectrometer (Varian, Palo.
Alto, CA, USA) with TMS as an internal standard. Mass spectra were recorded on a 1100 Series
G1956B LC/MSD SL LCMS system (Agilent, Santa Clara, CA, USA) using electrospray ionization at
atmospheric pressure (70 eV). X-ray structural analysis of a single crystal of compound 22 was
performed at 173 K on a Smart Apex II diffractometer (Bruker, Madison, WI, USA) operating in the
ω scans mode. The intensity data were collected within the range of 2.19 ≤ θ ≤ 26.72° using Mo-Kα
radiation (λ = 0.71078 Å). The intensities of 11,753 reflections were collected (2580 unique reflections,
Rmerg = 0.0526). The structure was solved by direct methods and refined by the full-matrix least-
squares technique in the anisotropic approximation for non-hydrogen atoms using the Bruker
SHELXTL program package [38]. All chemicals were of reagent grade and used without further
purification. The solvents were purified according to the standard procedures [39]. 1-Amino-9,10-
dioxo-9,10-dihydroanthracene-2-carboxylic
acid
(1)
and
1-amino-4-bromo-9,10-dioxo-9,10-
dihydroanthracene-2-carboxylic acid (2) were purchased from Sigma-Aldrich (St. Louis, MO, USA).
3.2. Chemistry
1-Amino-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (5). To 1-amino-9,10-dioxo-9,10-dihydro-
anthracene-2-carboxylic acid (1, 0.5 g, 1.87 mmol) in benzene (30 mL) pyridine (0.023 mL, 0.28 mmol)
and thionyl chloride (0.41 mL, 5.61 mmol) were added and the mixture boiled for 5 h at 80 °C with a
calcium chloride drying tube. The reaction mixture was cooled to room temperature. The solvent was
distilled off under vacuum. The residue was added portionwise to 25% ammonia solution (50 mL) at
−15 ° C and kept at this temperature for 1 h. After the mixture was gradually heated to 80 °C, kept at
this temperature for 3 h, then cooled to room temperature, acidified with 10% HCl to pH = 6, filtered
and washed with water. Compound 3 did not require additional purification. Yield 90%; m.p.: 299–
1
300 °C (298–299 °C in [40]); H-NMR: δ = 7.31 (d, 2H, NH2), 7.61 (m, 1HAr), 7.79–7.84 (m, 2H, NH2),
13
7.98–8.13 (m, 4HAr), 9.05 (s, 1HAr). C-NMR: δ = 113.21, 113.31, 121.77, 126.12, 126.45, 132.06, 133.45,
134.26, 134.52, 135.17, 135.68 (CAr), 151.96 (C-NH2); 169.76, 182.43, 183.98 (C=O). LC-MS (70 eV): m/z =
+
267 [M + 1] (100%). Anal. Calcd. for C15H10N2O3: C, 67.67; H, 3.79; N, 10.52. Found: C, 67.75; H, 3.72;
N, 10.58.
1-Amino-4-bromo-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (14). This compound was obtained
1
similarly to 5. Yield 89%; m.p. > 300 °C: H-NMR (CF3COOD): δ = 7.56–8.03 (m, 4H, HAr+NH2), 8.11–
13
8.84 (m, 5H, HAr+NH2). C-NMR (CF3COOD): δ = 122.38, 125.82, 127.57, 127.72, 132.13, 132.88, 134.31,
135.04, 135.08, 135.67, 136.37 (CAr), 142.13 (C-NH2); 169.92, 182.62, 185.96 (C=O). LC-MS (70 eV): m/z =
+
346 [M + 1] (100%). Anal. Calcd. for C15H9BrN2O3: C, 52.20; H, 2.63; N, 8.12. Found: C, 52.26; H, 2.69;
N, 8.17.

Molecules 2019, 24, 4581
11 of 20
3.2.1. General Procedure for the Synthesis of Amides 6–13, 15–21
To the corresponding amino acid 1 or 2 (1.87 mmol) in benzene (30 mL), pyridine (0.023 mL, 0.28
mmol) and thionyl chloride (0.41 mL, 5.61 mmol) were added. The mixture was boiled for 5 h at 80
°C with a calcium chloride drying tube, and then the solvent was distilled off under vacuum. Benzene
(30 mL) was added to the resulting residue at room temperature, then the corresponding aniline (2.06
mmol) and triethylamine (0.29 mL, 2.06 mmol) were added (in the case of cyclohexylamine, N,N-
diisopropylethylamine was used). The mixture was boiled at 80 °C for 12 h, cooled to room
temperature and the solvent was distilled off under vacuum. The resulting precipitate was
suspended in water (100 mL), filtered, washed with water (150 mL and dried. If necessary, amides
can be recrystallized from acetic acid.
1-Amino-9,10-dioxo-N-(2-(trifluoromethyl)phenyl)-9,10-dihydroanthracene-2-carboxamide (6). Yield 89%;
1
m.p.: 180–182 °C (sublimation); H-NMR: δ = 7.49 (d, J = 7.8 Hz, 1HAr), 7.59 (t, J = 8.3 Hz, 2HAr), 7.74–
7.93 (m, 5HAr), 8.12 (d, J = 7.3 Hz, 2HAr), 8.20 (d, J = 7.6 Hz, 1HAr), 8.77 (s, 1HAr), 10.42 (br.s, 1H, NH).
13
C-NMR: δ = 114.01, 119.68 (q, J = 32 Hz, C-CF3), 122.65, 125.55 (q, J = 268 Hz, CF3), 126.75, 127.06,
128.32, 131.84, 132.64, 133.70, 134.15, 134.76, 135.17, 135.67, 136.54, 151.94 (CAr); 167.91, 182.98, 184.66
+
(C=O). LC-MS (70 eV): m/z = 411 [M + 1] (100%). Anal. Calcd. for C22H13F3N2O3: C, 64.39; H, 3.19; N,
6.83. Found: C, 64.39; H, 3.15; N, 6.87.
1-Amino-9,10-dioxo-N-(m-tolyl)-9,10-dihydroanthracene-2-carboxamide (7). Yield 91%; m.p.: 225–226 °C;
1
H-NMR: δ = 2.31 (s, 3H, CH3), 6.94 (d, J = 6.2 Hz, 1HAr), 7.23 (t, J = 7.0 Hz, 1HAr), 7.43–7.63 (m, 5H,
13
HAr+NH2), 7.86 (dd, J = 22.9, 6.0 Hz, 2HAr), 8.02-8.22 (m, 3HAr), 10.39 (br s, 1H, NH). C-NMR: δ = 21.68
(CH3), 113.75, 114.14, 118.34, 121.69, 125.30, 126.74, 127.08, 128.95, 132.67, 134.11, 134.80, 135.14, 135.69,
+
136.13, 138.31, 139.01 (CAr), 166.54, 182.98, 184.63 (C=O). LC-MS (70 eV): m/z = 357 [M + 1] (100%).
Anal. Calcd. for C22H16N2O3: C, 74.15; H, 4.53; N, 7.86. Found: C, 74.09; H, 4.51; N, 7.91.
1-Amino-N-cyclohexyl-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (8). Yield 91%; m.p.: 289-290 °C
1
(289–290 °C in [40]); H-NMR: δ = 1.29 (m, 6H, CH2), 1.59-1.91 (m, 4H, CH2), 3.76 (s, 1H, CH), 7.36 (s,
13
3HAr, CH+NH2), 7.89 (m, 3HAr), 8.15 (m, 3HAr, CH+NH). C-NMR: δ = 25.03, 30.79, 32.66 (CH2), 48.76
(CH), 114.16, 127.07, 128.80, 132.69, 134.12, 135.17, 135.75, 135.82, 151.74 (CAr), 166.91, 183.07, 184.59
+
(C=O). LC-MS (70 eV): m/z = 349 [M + 1] (100%). Anal. Calcd. for C21H20N2O3: C, 72.40; H, 5.79; N,
8.04. Found: C, 72.45; H, 5.75; N, 8.01.
1-Amino-N-(3-fluorophenyl)-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (9). Yield 90%; m.p.: 240–
1
242 °C; H-NMR: δ = 6.95 (t, J = 7.6 Hz, 1HAr), 7.32–7.54 (m, 4H, HAr+NH2), 7.69 (d, J = 11.4 Hz, 1HAr),
13
7.80–7.93 (m, 3HAr), 8.07 (dd, J = 21.4, 6.6 Hz, 2HAr), 8.15–8.20 (m, 1HAr), 10.63 (s, 1H, NH). C-NMR:
δ = 113.83, 114.07, 116.78, 124.05, 126.74, 127.08, 130.70, 130.77, 132.64, 134.15, 134.76, 135.17, 135.80,
136.32, 140.81, 151.59 (CAr), 162.49 (d, J = 241.1 Hz, C-F), 166.78, 182.96, 184.65 (C=O). LC-MS (70 eV):
+
m/z = 361 [M + 1] (100%). Anal. Calcd. for C21H13FN2O3: C, 70.00; H, 3.64; N, 7.77. Found: C, 70.03; H,
3.60; N, 7.74.
1-Amino-N-(4-fluorophenyl)-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (10). Yield 88%; m.p.: 262–
1
264 °C; H-NMR: δ = 7.19 (s, 2HAr), 7.32–7.44 (m, 2H, NH2), 7.73 (s, 2HAr), 7.83 (d, J = 28.3 Hz, 3HAr),
13
8.01–8.09 (m, 2H), 8.13–8.17 (m, 1HAr), 10.50 (br s, 1H, NH). C-NMR: δ = 116.08, 117.89, 124.37, 125.17,
125.50, 126.27, 129.05, 130.95, 134.78, 136.28, 136.92, 137.30, 137.72, 138.34, 153.78 (CAr), 161.19 (d, J =
+
241.4, C-F), 168.64, 185.11, 186.77 (C=O). LC-MS (70 eV): m/z = 361 [M + 1] (100%). Anal. Calcd. for
C21H13FN2O3: C, 70.00; H, 3.64; N, 7.77. Found: C, 69.98; H, 3.61; N, 7.79.
1-Amino-N-(3-chlorophenyl)-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (11). Yield 87%; m.p.: 252–
1
253 °C; H-NMR (CF3COOD): δ = 7.39–7.45 (m, 4HAr), 7.67 (s, 1H), 8.05 (m, 2HAr), 8.44 (d, J = 11.0 Hz,
13
4HAr), 8.56 (d, J = 7.4 Hz, 1HAr), 11.52 (s, 1H, NH). C-NMR (CF3COOD): δ = 116.95, 123.90, 125.89,
128.14, 130.79, 131.25, 132.20, 133.49, 135.10, 135.27, 135.91, 137.39, 138.17, 139.03, 139.62, 140.06 (CAr),
+
168.73, 185.40, 189.75 (C=O). LC-MS (70 eV): m/z = 377 [M + 1] (100%). Anal. Calcd. for C21H13ClN2O3:
C, 66.94; H, 3.48; N, 7.43. Found: C, 66.99; H, 3.43; N, 7.45.

Molecules 2019, 24, 4581
12 of 20
1-Amino-N-(4-chlorophenyl)-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (12). Yield 89%; m.p.: 265–
1
266 °C; H-NMR (CF3COOD): δ = 7.38–7.45 (m, 4H, HAr+NH2), 7.97 (m, 3HAr), 8.33–8.39 (m, 4HAr), 8.70
13
(s, 1HAr), 11.51 (s, NH). C-NMR (CF3COOD): δ = 123.77, 124.02, 125.43, 128.38, 129.52, 129.67, 130.43,
131.52, 132.04, 132.84, 132.91, 133.07, 133.96, 134.46, 136.29, 136.57, 136.89 (CAr), 165.69, 182.76, 186.67
+
(C=O). LC-MS (70 eV): m/z = 377 [M + 1] (100%). Anal. Calcd. for C21H13ClN2O3: C, 66.94; H, 3.48; N,
7.43. Found: C, 66.93; H, 3.50; N, 7.41.
1-Amino-N-(2-methoxyphenyl)-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (13). Yield 89%; m.p.:
1
187–189 °C [41]; H-NMR (CF3COOD): δ = 3.90 (s, 3H, OCH3), 7.03 (t, J = 7.4 Hz, 2HAr), 7.30 (t, J = 8.3
Hz, 1HAr), 7.77 (d, J = 7.6 Hz, 1HAr), 7.97 (m, 3HAr), 8.38 (m, 3HAr), 8.47 (d, J = 8.2 Hz, 1HAr), 8.71 (d, J =
13
8.2 Hz, 1HAr), 11.52 (s, NH). C-NMR (CF3COOD): δ = 55.09 (CH3), 111.43, 121.19, 123.10, 123.37,
127.85, 128.29, 128.86, 129.71, 131.28, 131.93, 132.81, 133.17, 134.20, 136.22, 136.49 (CAr), 151.10, 182.68,
+
186.54 (C=O). LC-MS (70 eV): m/z = 373 [M + 1] (100%). Anal. Calcd. for C22H16N2O4: C, 70.96; H, 4.33;
N, 7.52. Found: C, 70.92; H, 4.30; N, 7.56.
1-Amino-4-bromo-N-(3-fluorophenyl)-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (15). Yield 90%;
1
m.p.: 253–255 °C; H-NMR: δ = 6.95 (s, 1HAr), 7.34–7.47 (m, 4H, NH2+HAr), 7.77–7.84 (m, 3HAr), 8.04 (d,
13
J = 20.7 Hz, 2H), 8.15 (m, 1HAr), 10.72 (s, 1H, NH). C-NMR: δ = 126.53, 126.77, 130.76, 133.18, 133.47,
133.73, 134.22, 134.73, 141.77, 151.05 (CAr), 162.44 (d, J = 241.0 Hz, C-F), 165.25, 182.37, 184.04 (C=O).
+
LC-MS (70 eV): m/z = 440 [M + 1] (100%). Anal. Calcd. for C21H12BrFN2O3: C, 57.42; H, 2.75; N, 6.38.
Found: C, 57.47; H, 2.71; N, 6.43.
1-Amino-4-bromo-N-(2-methoxyphenyl)-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (16). Yield 91%;
1
m.p.: 225–226 °C; H-NMR: δ = 3.83 (s, 3H, CH3), 6.95-7.38 (m, 4HAr), 7.52–7.66 (m, 1HAr), 7.79–7.93 (m,
13
2H, NH2), 8.06-8.24 (m, 3HAr), 8.84 (m, 1H), 10.03 (s, 1H, NH). C-NMR: δ = 56.20 (CH3), 106.33, 112.19,
120.63, 126.23, 126.45, 126.61, 126.84, 127.34, 128.80, 133.32, 133.41, 133.87, 134.31, 134.83, 141.82,
+
151.18, 153.00 (CAr), 161.38, 182.57, 184.15 (C=O). LC-MS (70 eV): m/z = 452 [M + 1] (100%). Anal.
Calcd. for C22H15BrN2O4: C, 58.55; H, 3.35; N, 6.21. Found: C, 58.59; H, 3.31; N, 6.24.
1-Amino-4-bromo-N-cyclohexyl-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (17). Yield 89%; m.p.:
1
>300 °C (298–299 °C in [40]); H-NMR: δ = 1.29 (m, 5H, CH2), 1.78 (m, 5H, CH2), 3.73 (m, 1H, CH), 7.35
13
(s, 1HAr), 7.81–7.88 (s, 2H, NH2), 7.99–8.13 (m, 4HAr), 8.65 (s, 1HAr). C-NMR: δ = 25.32, 25.68, 32.58
(CH2), 48.90 (CH), 124.81, 126.52, 126.59, 126.80, 128.81, 129.22, 133.02, 133.25, 133.83, 134.21, 134.76,
+
141.22 (CAr), 165.46, 182.50, 182.63 (C=O). LC-MS (70 eV): m/z = 428 [M + 1] (100%). Anal. Calcd. for
C21H19BrN2O3: C, 59.03; H, 4.48; N, 6.56. Found: C, 59.00; H, 4.51; N, 6.59.
1-Amino-4-bromo-N-(4-fluorophenyl)-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (18). Yield 87%;
1
m.p.: 273–275 °C; H-NMR: δ = 7.19 (s, 2HAr), 7.71 (s, 2H, NH2), 7.81 (s, 3HAr), 8.05 (d, J = 22.5 Hz, 3HAr),
13
8.15 (s, 1HAr), 10.61 (s, 1H, NH). C-NMR: δ = 106.32, 115.82, 123.09, 123.26, 124.84, 126.53, 126.77,
133.20, 133.75, 134.22, 134.73, 141.68, 150.98 (CAr), 159.15 (d, J = 241.1 Hz, C-F), 164.97, 182.39, 184.04
+
(C=O). LC-MS (70 eV): m/z = 440 [M + 1] (100%). Anal. Calcd. for C21H12BrFN2O3: C, 57.42; H, 2.75; N,
6.38. Found: C, 57.46; H, 2.71; N, 6.43.
1-Amino-4-bromo-N-(3-chlorophenyl)-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (19). Yield 90%;
1
m.p.: 243–245 °C; H-NMR (CF3COOD): δ = 7.21–7.44 (m, 4H, HAr+NH2), 7.80–8.05 (m, 4HAr), 8.21–8.39
13
(m, 3HAr), 11.51 (1H, NH). C-NMR (CF3COOD): δ = 119.06, 119.96, 120.91, 122.20, 124.11, 126.23,
126.70, 127.14, 129.32, 130.63, 132.35, 133.91, 135.05, 137.34, 138.29, 141.87, 150.38 (CAr), 166.14, 182.88,
+
184.50 (C=O). LC-MS (70 eV): m/z = 456 [M + 1] (100%). Anal. Calcd. for C21H12BrClN2O3: C, 55.35; H,
2.65; N, 6.15. Found: C, 55.39; H, 2.61; N, 6.18.
1-Amino-4-bromo-N-(4-chlorophenyl)-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (20). Yield 87%;
1
m.p.: 255–256 °C; H-NMR: δ = 7.44 (d, J = 8.6 Hz, 2HAr), 7.76 (d, J = 8.6 Hz, 2HAr), 7.85–7.92 (m, 4HAr),
13
8.10 (d, J = 7.2 Hz, 1HAr), 8.17 (d, J = 7.5 Hz, 1HAr), 8.20 (s, 1HAr), 10.74 (s, 1H, NH). C-NMR: δ = 115.14,
122.27, 124.52, 126.08, 126.31, 127.94, 128.55, 132.76, 132.97, 133.30, 133.79, 137.34, 141.25, 150.48 (CAr),
+
164.60, 181.99, 183.64 (C=O). LC-MS (70 eV): m/z = 456 [M + 1] (100%). Anal. Calcd. for
C21H12BrClN2O3: C, 55.35; H, 2.65; N, 6.15. Found: C, 55.33; H, 2.62; N, 6.13.

Molecules 2019, 24, 4581
13 of 20
1-Amino-4-bromo-9,10-dioxo-N-(2-(trifluoromethyl)phenyl)-9,10-dihydroanthracene-2-carboxamide
Yield 89%; m.p.: 285–286 °C (sublimation); H-NMR: δ = 7.56–7.66 (m, 2HAr), 7.76 (d, J = 7.6 Hz, 1HAr),
(21).
1
7.82 (d, J = 8.0 Hz, 1HAr), 7.88-7.91 (m, 2HAr), 8.13 (d, J = 7.5 Hz, 2HAr), 8.20 (d, J = 7.7, 1HAr), 8.28 (s,
13
1HAr), 8.84 (s, 1HAr), 10.48 (s, 1H, NH). C-NMR: δ = 116.12, 119.76 (q, J = 35.2 Hz, C-CF3), 123.86,
124.55 (q, J = 268 Hz, CF3), 126.61, 126.82, 128.35, 131.61, 133.41, 133.63, 133.95, 134.28, 134.77, 141.82,
+
151.38 (CAr), 166.55, 182.52, 184.22 (C=O). LC-MS (70 eV): m/z = 490 [M + 1] (100%). Anal. Calcd. for
C22H12BrF3N2O3: C, 54.01; H, 2.47; N, 5.73. Found: C, 54.04; H, 2.43; N, 5.76.
3.2.2. General Procedure for the Synthesis of Anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones 22–38
To the corresponding amide 5–13 (1.88 mmol) in glacial acetic acid (50 mL) (in the case of amides
14–21 100–150 mL of glacial acetic acid was used), a first portion of NaNO2 (0.168 g, 2.44 mmol) in
water (1.5 mL) was added with the stirring at room temperature, After 3 h, the same amount of
NaNO2 in water (1.5 mL) was added. The mixture was stirred for 9 h at room temperature and then
filtered. The filtrate was poured into water (200 mL, in the case of amides 14–21 600 mL of water),
acidified with a 10% HCl solution to pH = 6. The resulting precipitate was filtered off, washed with
water and dried in air.
1
Anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (22). Yield 90%; m.p.: 140-142 °C (decomposition); H-
13
NMR: δ = 7.88–7.91 (m, 2HAr), 8.10 (m, 2HAr), 8.49–8.33 (m, 2HAr), 15.38 (1H, br s, NH). C-NMR: δ =
124.43, 126.82, 127.17, 129.57, 130.39, 132.19, 134.58, 135.17, 135.53, 139.03, 141.94 (CAr); 155.22, 182.04,
+
182.28 (C=O). LC-MS (70 eV): m/z = 278 [M + 1] (100%). Anal. Calcd. for C15H7N3O3: C, 64.99; H, 2.55;
N, 15.16. Found: C, 65.01; H, 2.51; N, 15.19.
Crystallography: X-ray structure determination of compound 22. Crystal data for 22: C15H7N3O4 ˣH2O, M =
295.25, monoclinic, space group P21/c, a = 7.070(3), b = 12.687(5), c = 13.816(5) Å, β = 95.842(11)°, V =
3
−3
−1
1232.9(8)Å , Z = 4, dc = 1.591 g·cm , µ = 0.119 mm , F(000) = 608, crystal size ca. 0.09 × 0.11 × 0.50 mm.
All CH hydrogen atoms were placed at calculated positions and refined as ‘riding’ model and NH
hydrogen atom was located at DF synthesis and refined isotropically. Convergence was obtained at
R1 = 0.0613 and wR2 = 0.1134 for 1319 observed reflections with I ≥ 2σ(I), R1 = 0.1465 and wR2 =
0.1474, GOF = 1.039 for 2580 independent reflections, 211 parameters, the largest and minimal peaks
3
in the final difference map 0.18 and −0.18 e/Å . Full crystallographic details have been deposited at
Cambridge Crystallographic Data Centre (CCDC). Any request to the CCDC for these materials
should quote the full literature citation and reference number CCDC 1966785.
3-(2-(Trifluoromethyl)phenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (23). Yield 72%; m.p.: 225–226
1
°C (decomposition); H-NMR (400 MHz, DMSO-d6): δ = 7.89 (t, J = 7.5 Hz, 1HAr), 7.94–8.01 (m, 4HAr),
8.06 (d, J = 7.8 Hz, 1HAr), 8.20 (d, J = 7.4 Hz, 2HAr), 8.69 (d, J = 8.2 Hz, 1HAr), 8.74 (d, J = 8.2 Hz, 1HAr).
13
C-NMR (100 MHz, DMSO-d6): δ = 119.01 (q, J = 32 Hz, C-CF3), 122.44, 123.81, 124.46, 125.03 (q, J =
273 Hz, CF3), 126.42, 126.91, 127.27, 127.98, 129.84, 130.99, 131.70, 132.38, 134.73, 135.26, 135.56, 136.33,
+
139.54, 140.84 (CAr); 154.80, 182.00, 182.14 (C=O). LC-MS (70 eV): m/z = 422 [M + 1] (100%). Anal.
Calcd. for C22H10F3N3O3: C, 62.72; H, 2.39; N, 9.97. Found: C, 62.67; H, 2.43; N, 10.01.
3-(m-Tolyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (24). Yield 73%; m.p.: 230-231 °C
1
(decomposition); H-NMR: δ = 1.90 (s, 3H, CH3), 7.39-7.60 (m, 3HAr), 7.88–8.03 (m, 3HAr), 8.20 (d, J =
13
8.4 Hz, 2HAr), 8.59-8.76 (m, 2HAr). C-NMR: δ = 124.02, 124.41, 126.90, 127.25, 127.30, 129.32, 129.40,
130.33, 130.97, 132.35, 134.68, 135.13, 135.19, 135.57, 138.92, 139.09, 140.87 (CAr); 154.41, 182.04, 182.26
+
(C=O). LC-MS (70 eV): m/z = 368 [M + 1] (100%). Anal. Calcd. for C22H13N3O3: C, 71.93; H, 3.57; N,
11.44. Found: C, 71.97; H, 3.52; N, 11.46.
3-Cyclohexylanthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (25). Yield 71%; m.p.: 215 °C (decomposition);
1
H-NMR: δ = 1.54 (dd, J = 36.6, 9.0 Hz, 4H, CH2), 1.88-2.08 (m, 6H, CH2), 4.82-4.95 (m, 1H, CH), 7.86–
13
7.97 (m, 2HAr), 8.12 (s, 2HAr), 8.45–8.60 (m, 2HAr). C-NMR: δ = 25.45, 25.71, 31.81 (CH2), 57.02 (C-H),
123.12, 126.84, 127.25, 129.00, 129.73, 130.88, 131.93, 133.44, 134.61, 135.54, 138.90, 140.94 (CAr); 153.92,
+
181.97, 182.28 (C=O). LC-MS (70 eV): m/z = 360 [M + 1] (100%). Anal. Calcd. for C21H17N3O3: C, 70.18;
H, 4.77; N, 11.69. Found: C, 70.21; H, 4.74; N, 11.72.

Molecules 2019, 24, 4581
14 of 20
3-(3-Fluorophenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (26). Yield 69%; m.p.: 225 °C
1
(decomposition); H-NMR: δ = 7.39–7.49 (m, 1HAr), 7.58–7.73 (m, 3HAr), 7.91–7.99 (m, 2HAr), 8.15–8.23
13
(m, 2HAr), 8.59–8.74 (m, 2HAr). C-NMR: δ = 116.61, 116.78, 123.21, 124.40, 126.93, 127.27, 127.32,
129.46, 130.50, 130.96, 131.29, 132.40, 134.70, 135.22, 135.57, 140.74 (CAr), 162.12 (d, J = 246.0 Hz, C-F),
+
154.39, 182.03, 182.22 (C=O). LC-MS (70 eV): m/z = 372 [M + 1] (100%). Anal. Calcd. for C21H10FN3O3:
C, 67.93; H, 2.71; N, 11.32. Found: C, 67.96; H, 2.68; N, 11.36.
3-(4-Fluorophenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (27). Yield 75%; m.p.: 230–232 °C
1
(decomposition); H-NMR: δ = 7.42–7.56 (m, 2HAr), 7.74–7.85 (m, 2HAr), 7.89–8.03 (m, 3H), 8.11–8.25
13
(m, 2H), 8.66 (d, J = 30.3 Hz, 1H). C-NMR (100 MHz, CF3COOD): δ = 111.43, 116.21, 124.69, 128.37,
128.58, 130.15, 131.54, 131.78, 134.51, 134.69, 136.54, 137.13, 140.00, 142.25 (CAr), 162.05 (d, J = 248.6 Hz,
+
C-F), 160.19, 178.17, 178.75 (C=O). LC-MS (70 eV): m/z = 372 [M + 1] (100%). Anal. Calcd. for
C21H10FN3O3: C, 67.93; H, 2.71; N, 11.32. Found: C, 67.89; H, 2.73; N, 11.29.
3-(3-Chlorophenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (28). Yield 69%; m.p.: 233 °C
1
(decomposition); H-NMR (CF3COOD): δ = 7.29 (d, J = 7.6 Hz, 1HAr), 7.35 (t, J = 8.0 Hz, 1HAr), 7.41 (d,
J = 7.8 Hz, 1HAr), 7.64 (s, 1HAr), 8.00–8.03 (m, 2HAr), 8.44 (dd, J = 11.4 Hz, 8.7, 2HAr), 8.85 (d, J = 8.2 Hz,
13
1HAr), 9.23 (d, J = 8.2 Hz, 1HAr). C-NMR (CF3COOD): δ = 111.50, 120.29, 122.43, 128.04, 128.45, 128.66,
130.39, 131.60, 131.86, 134.51, 134.78, 135.52, 136.62, 137.19, 140.08, 142.35 (CAr), 160.02, 178.23, 178.80
+
(C=O). LC-MS (70 eV): m/z = 388 [M + 1] (100%). Anal. Calcd. for C21H10ClN3O3: C, 65.05; H, 2.60; N,
10.84. Found: C, 65.08; H, 2.56; N, 10.81.
3-(4-Chlorophenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (29). Yield 67%; m.p.: 251 °C
1
(decomposition); H-NMR (CF3COOD): δ = 7.39 (d, J = 7.3 Hz, 2HAr), 7.52 (d, J = 7.0 Hz, 2HAr), 8.00–
13
8.05 (m, 2HAr), 8.41–8.47 (m, 2HAr), 8.82–8.90 (m, 1HAr), 9.20–9.27 (m, 1HAr). C-NMR (CF3COOD): δ
= 111.42, 123.52, 128.38, 128.59, 129.47, 131.55, 131.78, 132.89, 134.51, 134.71, 136.55, 137.09, 137.17,
+
140.02, 142.34 (CAr), 159.89, 178.17, 178.76 (C=O). LC-MS (70 eV): m/z = 388 [M + 1] (100%). Anal.
Calcd. for C21H10ClN3O3: C, 65.05; H, 2.60; N, 10.84. Found: C, 65.02; H, 2.58; N, 10.86.
3-(2-Methoxyphenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (30). Yield 78%; m.p.: 216 °C
1
(decomposition); H-NMR (CF3COOD): δ = 3.90 (s, 3H, CH3), 7.06 (d, J = 8.1 Hz, 1HAr), 7.33 (t, J = 7.8
Hz, 1HAr), 7.80 (d, J = 7.8 Hz, 1HAr), 8.00–8.03 (m, 3HAr), 8.44 (dd, J = 10.8 Hz, 8.9 Hz, 2HAr), 8.82 (d, J =
13
8.1 Hz, 1HAr), 9.24 (d, J = 8.2 Hz, 1HAr). C-NMR (CF3COOD): δ = 55.18 (CH3), 111.51, 121.27, 123.01,
123.48, 128.64, 131.58, 131.85, 134.44, 134.73, 136.60, 137.11, 137.23, 140.13, 142.59 (CAr);, 151.26 (C-
+
OMe), 159.80, 178.24, 178.81 (C=O). LC-MS (70 eV): m/z = 384 [M + 1] (100%). Anal. Calcd. for
C22H13N3O4: C, 68.93; H, 3.42; N, 10.96. Found: C, 68.95; H, 3.39; N, 10.99.
1
6-Bromoanthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (31). Yield 78%; m.p.: 155 °C (decomposition); H-
13
NMR: δ = 7.92 (d, J = 3.4 Hz, 2HAr), 8.08 (d, J = 8.8 Hz, 2HAr), 8.67 (s, 1HAr), 15.45 (br s, 1H, NH). C-
NMR: δ = 123.54, 124.15, 126.32, 126.93, 133.50, 134.41, 134.67, 135.00, 135.72, 141.04 (CAr); 153.96,
+
181.71, 181.94 (C=O). LC-MS (70 eV): m/z = 357 [M + 1] (100%). Anal. Calcd. for C15H6BrN3O3: C, 50.59;
H, 1.70; N, 11.80. Found: C, 50.62; H, 1.67; N, 11.83.
6-Bromo-3-(3-fluorophenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (32). Yield 65%; m.p.: 235–237
1
°C (decomposition); H-NMR: δ = 7.37–7.52 (m, 1HAr), 7.65 (m, 2HAr), 7.87–8.02 (m, 2HAr), 8.08–8.30
13
(m, 3HAr), 8.62–8.91 (m, 1HAr). C-NMR (CF3COOD): δ = 109.25, 109.46, 109.81, 114.55, 114.73, 117.37,
128.11, 128.52, 130.73, 132.79, 134.91, 135.71, 135.99, 137.69, 139.56, 140.02, 141.82 (CAr), 163.11 (d, J =
+
246.5 Hz, C-F), 159.03, 177.56, 178.28 (C=O). LC-MS (70 eV): m/z = 451 [M + 1] (100%). Anal. Calcd.
for C21H9BrFN3O3: C, 56.02; H, 2.01; N, 9.33. Found: C, 56.05; H, 1.99; N, 9.36.
6-Bromo-3-(2-methoxyphenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (33). Yield 67%; m.p.: 240 °C
1
(decomposition); H-NMR: δ = 3.80 (s, 3H, CH3), 7.17–7.34 (m, 2HAr), 7.56–7.64 (m, 2HAr), 7.95 (s, 2HAr),
13
8.11–8.20 (m, 2HAr), 8.80 (s, 1HAr). C-NMR: δ = 56.44 (CH3), 113.14, 121.25, 123.51, 124.66, 126.42,
127.01, 127.31, 129.40, 132.12, 133.69, 134.46, 134.76, 135.03, 136.90, 140.07 (CAr); 152.80 (C-OMe),
+
154.86, 181.68, 181.89 (C=O). LC-MS (70 eV): m/z = 463 [M + 1] (100%). Anal. Calcd. for C22H12BrN3O4:
C, 57.16; H, 2.62; N, 9.09. Found: C, 57.12; H, 2.66; N, 9.05.

Molecules 2019, 24, 4581
15 of 20
6-Bromo-3-cyclohexylanthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (34). Yield 65%; m.p.: 242–243 °C
1
(decomposition); H-NMR: δ = 1.20–1.54 (m, 6H, CH2), 1.69–1.95 (m, 4H, CH2), 4.82–4.93 (m, 1H, CH),
13
7.92 (s, 2HAr), 8.08 (s, 2HAr), 8.66 (s, 1HAr). C-NMR: δ = 25.40, 25.66, 31.71 (CH2), 57.22 (CH), 122.76,
123.65, 126.31, 126.91, 132.99, 133.40, 134.26, 134.69, 134.99, 136.37, 139.94 (CAr); 152.58, 181.58, 181.71
+
(C=O). LC-MS (70 eV): m/z = 439 [M + 1] (100%). Anal. Calcd. for C21H16BrN3O3: C, 57.55; H, 3.68; N,
9.59. Found: C, 57.58; H, 3.64; N, 9.62.
6-Bromo-3-(4-fluorophenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (35). Yield 67%; m.p.: 223 °C
1
(decomposition); H-NMR: δ = 7.48 (dd, J = 9.2 Hz, 4.7 Hz, 2HAr), 7.72–7.79 (m, 2HAr), 7.90–7.98 (m,
13
2HAr), 8.11–8.18 (m, 2HAr), 8.78 (s, 1HAr). C-NMR: δ = 109.84, 116.16, 116.35, 124.36, 124.43, 128.15,
128.55, 130.18, 130.32, 132.84, 134.97, 137.55, 137.71, 139.52, 140.04, 141.91 (CAr), 162.08 (d, J = 248.7 Hz,
+
C-F), 159.32, 177.61, 178.30 (C=O). LC-MS (70 eV): m/z = 451 [M + 1] (100%). Anal. Calcd. for
C21H9BrFN3O3: C, 56.02; H, 2.01; N, 9.33. Found: C, 56.05; H, 1.97; N, 9.36.
6-Bromo-3-(3-chlorophenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (36). Yield 65%; m.p.: 211 °C
1
(decomposition); H-NMR (CF3COOD): δ = 7.27 (d, J = 7.8 Hz, 1HAr), 7.33 (t, J = 7.9 Hz, 1HAr), 7.39 (d,
13
J = 7.6 Hz, 1HAr), 7.63 (s, 1HAr), 7.98 (m, 2HAr), 8.35–8.40 (m, 2HAr), 9.02 (s, 1HAr). C-NMR (CF3COOD):
δ = 119.98, 122.10, 127.93, 128.18, 128.56, 130.34, 130.37, 135.48, 135.60, 136.06, 137.58, 137.73, 140.05,
+
141.90 (CAr), 159.04, 177.61, 178.24 (C=O). LC-MS (70 eV): m/z = 467 [M + 1] (100%). Anal. Calcd. for
C21H9BrClN3O3: C, 54.05; H, 1.94; N, 9.00. Found: C, 54.08; H, 1.98; N, 9.03.
6-Bromo-3-(4-chlorophenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (37). Yield 63%; m.p.: 223 °C
1
(decomposition); H-NMR (CF3COOD): δ = 7.40 (d, J = 8.4 Hz, 2HAr), 7.53 (d, J = 8.5 Hz, 2HAr), 8.00 (d,
13
J = 6.9 Hz, 1HAr), 8.04 (d, J = 7.4 Hz, 1HAr), 8.41 (d, J = 7.8 Hz, 2HAr), 9.05 (s, 1HAr). C-NMR (CF3COOD):
δ = 123.20, 128.14, 128.54, 129.50, 130.30, 132.80, 132.92, 133.99, 136.02, 137.54, 139.54, 139.98, 141.85
+
(CAr), 159.02, 177.59, 178.27 (C=O). LC-MS (70 eV): m/z = 467 [M + 1] (100%). Anal. Calcd. for
C21H9BrClN3O3: C, 54.05; H, 1.94; N, 9.00. Found: C, 54.03; H, 1.97; N, 9.02.
6-Bromo-3-(2-(trifluoromethyl)phenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (38). Yield 75%; m.p.:
1
242 °C (decomposition); H-NMR (CF3COOD): δ = 7.66 (d, J = 7.8 Hz, 1HAr), 7.72–7.78 (m, 1HAr), 7.89
13
(s, 1HAr), 8.04 (m, 3HAr), 8.42 (d, J = 7.7 Hz, 2HAr), 9.08 (s, 1HAr). C-NMR (CF3COOD): δ = 119.52 (q, J
= 32 Hz, C-CF3), 122.44, 123.81, 124.46, 125.32 (q, J = 273.05 Hz, CF3), 126.42, 126.91, 127.27, 127.98,
129.84 130.70, 131.48, 131.70, 132.38, 134.73, 135.26, 136.33, 139.54, 140.84 (CAr); 154.87, 177.63, 178.24
+
(C=O). LC-MS (70 eV): m/z = 501 [M + 1] (100%). Anal. Calcd. for C22H9BrF3N3O3: C, 52.82; H, 1.81; N,
8.40. Found: C, 52.86; H, 1.83; N, 8.36.
3.3. Biology
3.3.1. Bacterial Strains and Media
The antimicrobial potential of all synthesized compounds was evaluated against five reference
strains of bacteria: Staphylococcus aureus ATCC 25923, S. aureus ATCC 29213, S. epidermidis ATCC
12228, Pseudomonas aeruginosa ATCC 27853, and Escherichia coli ATCC 25,922 and four reference
strains of human pathogenic yeasts: C. albicans ATCC 10231, C. albicans SC5314, C. krusei DSM 6128
and C. glabrata DSM 11226. Because of the positive results of preliminary tests the anti-staphylococcal
activity of selected agents was also investigated against eight MSSA and four MRSA clinical isolates
derived from patients with different infections (Table 5). The antibiotics: ampicillin, oxacillin,
gentamicin, fusidic acid, levofloxacin, linezolid, daptomycin were purchased from Argenda (Poznan,
Poland). Bacteria were routinely grown on Luria-Bertani Agar (LA, Sigma Aldrich, Schnelldorf,
Germany) and yeasts were cultivated on YPD Agar (A&A Biotechnology, Gdynia, Poland). In the
case of bacteria, the Minimum Inhibitory Concentration (MIC) values were determined using
Mueller-Hinton Broth 2 (MHB2, Sigma Aldrich) liquid medium—and determination of the same
parameter for yeasts was performed using RPMI 1640 medium (Sigma Aldrich) supplemented with
2% glucose (Sigma Aldrich) and buffered to pH 7.0 with
a
MOPS buffer (3-N-
morpholinopropanesulfonic acid) (Sigma Aldrich). For staphylococcal biofilm formation, TSB (Sigma

Molecules 2019, 24, 4581
16 of 20
Aldrich) liquid medium supplemented with 2.5% of glucose was used and Time-Kill assay was
performed in Mueller-Hinton Broth 2.
Table 5. MSSA and MRSA strains used for investigation of antistaphylococcal potential of
synthesized agents.
Code of the
Strain
Ward of
Hospital
Intensive care
Internal
Antibiogram—Susceptibility
Profile 1
No.
Material
1
2
3
4
5
6
7
4471313
4475564
4476206
4475131
4466686
4466380
4466896
Nasal swab
Nasal swab
Sputum
Pus
Sputum
Wound
Nasal swab
Pharyngeal
swab
Pen.—R, Met.—S, Clin.—S, Ery.—S
Pen.—R, Met.—S, Clin.—R, Ery.—R
Pen.—R, Met.—S, Clin.—R, Ery.—R
Pen.—R, Met.—S, Clin.– R, Ery.—R
Pen.—R, Met.—S, Clin.—R, Ery.—R
Pen.—R, Met.—S, Clin.—S, Ery.—S
Pen.—R, Met.—S, Clin.—S, Ery.—S
Internal
Internal
Surgical
Surgical
Internal
8
4468792
9572250
8007171
Pediatrics
Internal
Pen.—R, Met.—S, Clin.—S, Ery.—S
Pen.—R, Met.—R, Clin.—R, Ery.—R
Pen.—R, Met.—R, Clin.—R, Ery.—R
9-MRSA
10-
MRSA
11-
MRSA
12-
Wound
Wound
Laryngology
45300223
9935169
Blood
Pediatrics
Pen.—R, Met—R, Clin.—R, Ery.—R
Pen.—R, Met.—R, Clin.—R, Ery.—R
Wound
Dispensary
MRSA
1
Identification of bacterial isolates and antibiograms were performed by Laboratory of Clinical
Microbiology, University Centre for Laboratory Diagnostics, Medical University of Gdańsk Clinical
Centre with Vitek2 Biomerieux system; Pen—Penicillin, Met—Methicillin, Clin—Clindamycin, Ery—
Erythromycin, R—resistant, S—sensitive.
3.3.2. Investigation of Antimicrobial Potential of Synthesized Agents
The two-fold broth microdilution method, according to the CLSI standard methodology [42],
was applied for the determination of minimum inhibitory concentrations (MICs) of synthesized
agents and antibiotics against bacteria (both reference strains and clinical isolates). Bacterial strains
were plated on Luria-Bertani Agar medium and incubated overnight at 37 °C. Two to three bacterial
colonies were transferred from the agar medium into PBS buffer (pH = 7.4). The bacterial suspension
was adjusted to the optical density of OD600 = 0.1 and diluted in MHB2 medium at a ratio of 1:100 v/v
6
to the final cell concentration of approximately 0.5–1.0 × 10 CFU/mL. The synthesized anthra[1,2-
d][1,2,3]triazine-4,7,12(3H)-triones were dissolved in DMSO—final concentration of all substances
tested in the stock solutions was 1280 µg/mL. The stock solutions with the same concentration (1280
µg/mL) of all antibiotics were used for investigation. Subsequently, a series of two-fold dilution of
each agent in range 64.0–0.0625 µg/mL were prepared in the wells of columns 1–10 of 96-well plates
using Mueller-Hinton Broth 2. An aliquot of 100 µL of inoculum was dispensed to the wells of
columns 1–11. Column 11 contained 200 µL of inoculum without any agent, and column 12 contained
200 µL of the MHB2 broth only (served as a control of medium sterility). The plates were incubated
24 h under static conditions at 37 °C. The lowest concentration of agent with no visible bacterial
growth was taken as a MIC value.
The determination of MIC values for yeast strains was also performed according to the
appropriate NCCLS reference microdilution method [43]. The solutions of substances in DMSO were
prepared in the same way as for the investigation of antibacterial activity (presented above). Serial
two-fold dilutions of the tested substances were prepared in RPMI 1640 medium buffered to pH 7.0
with MOPS buffer (3-N-morpholinopropanesulfonic acid) in 96-well microtiter plates in a final
volume of 100 µL. The final concentrations of the agents were in the range from 64 to 0.0625.
Suspensions of the microorganisms were prepared by taking one loop of pure culture (cultivated 24
h at 37 °C on YPD agar) into sterile water and adjusting the optical density to 0.1 at 660 nm
4
wavelength before further 50-fold dilution in an RPMI 1640 medium resulting in 2 × 10 CFU/mL.

Molecules 2019, 24, 4581
17 of 20
One hundred microliters of such suspension were inoculated to each well of the microtiter plate,
leaving a drug-free column (number 12) as sterility controls. Plates were incubated for 24 h at 37 °C.
MIC values were read visually as the first concentration where no growth was observed. The MIC
assay for each tested strain of bacteria/yeast and agent was performed in triplicate. In the case of both
assays (investigation of antibacterial and antifungal activity) the final concentration of the solvent
(DMSO) in the medium did not exceed 2.5% (v/v), and did not influence the growth of bacteria/yeast.
3.3.3. Time-Kill Assay
Taking into account the results of previously performed analysis (high activity against
staphylococci and lack of activity against Gram-negative bacteria and yeasts) the kinetic time-kill
assay was performed for one reference strain of staphylococci (namely S. aureus ATCC 29213) and
four, most promising, compounds (namely 32, 33, 34 and 36). The suspension of approx. cell density
6
0.5–1.0 × 10 CFU/mL of S. aureus ATCC 29,213 was prepared in MHB2 broth supplemented with a
particular agent to the final concentrations equal to MIC, 2 × MIC or 4 × MIC and incubated at 37 °C
with shaking (150 rpm). Bacterial suspension without agent addition was used as the untreated
control. At predetermined time intervals (0, 1, 3, 6 and 24 h) samples were taken, serially diluted in
−1
−7
PBS buffer (from 10 to 10 ) and spotted (10 µL) onto a Baird-Parker agar plate. After 24 h of
incubation, the plates were enumerated. For each agent the assay was repeated in triplicate.
3.3.4. Biofilm Formation and Determination of Antibiofilm Activity
The assay for biofilm cultivation was performed according to the procedure described
8
previously [44] with slight modifications. The suspensions of approx. cell density 1-5 × 10 CFU/mL
of S. aureus ATCC 29,213 were diluted 1:100 (v/v) in TSB medium supplemented with 2.5% glucose.
Cell suspensions (200 µL) were placed into the wells of columns 1–7 of vertically set plates. The wells
of column 8 were fulfilled with 200 µL of sterile medium—these wells were used as a negative
control. The plates were incubated for 24 h at 37 °C without shaking in order to allow bacteria to
attach. In the next step, the formed biofilm was treated with four selected, most promising agents (32,
33, 34 and 36). The liquid medium was removed from the wells of the plates and the formed biofilm
was gently washed with 200 µL of sterile PBS. Subsequently 200 µL of 2-fold serial dilutions of the
agents in MHB2 medium, ranging from 64 to 2 µg/mL, were added to the wells of columns 1-6
(column 7—without agent but with formed biofilm served as positive control and wells of column
8—without biofilm, were used as negative control–control of sterility of the medium) and incubated
for 24 h at 37 °C. The MTT assay was performed as described previously [44,45]. After 24-h treatment,
the liquid content of the wells of the plates was removed and the treated biofilm was washed with
200 µL of sterile PBS buffer. Subsequently, 150 µL of PBS and 50 µL of MTT solution (0.3% in PBS)
were added to the wells and mixed. Following 2 h incubation at 37 °C in the dark, the MTT solution
was replaced with 200 µL of DMSO for dissolving the formed formazan crystals. The optical density
3
of the obtained solutions was measured at 540 nm using a Victor microtiter reader (Perkin Elmer,
Waltham, MA, USA). The Minimal Biofilm Eradiation Concentration (MBEC50) values were taken as
the lowest concentration of the agent that caused eradication of at least 50% of living cells in
comparison to the cells growing in the untreated control—measured as comparison of ability of living
cells to the biotransformation of MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide) to insoluble in water violet formazan crystals [45].
3.3.5. Influence of Investigated Agents on Enzymatic Activity of S. aureus
Fresh suspension (in PBS) of S. aureus ATCC 29,213 OD600 = 0.5 was exposed to the action of the
selected tested agents (32, 33, 34 and 36) at concentration equal to ½ MIC for 1 h, 37 °C and then
washed three times with PBS in order to avoid ‘carryover’ effect. Next, 65 microliters of the
suspension were loaded to the cupules of the API ZYM strips. Suspension of untreated cells of S.
aureus ATCC 29,213 served as controls. The strips API ZYM were incubated for 4 h at 37 °C and the
results were read according to the manufacturer’s instructions. Enzymatic activity was determined

Molecules 2019, 24, 4581
18 of 20
in nanomoles of the hydrolyzed substrate according to the intensity of the color reaction on the scale
1–5, i.e., 1–5 nanomoles, 2–10, 3–20, 4–30, and 5–40 and more nanomoles. The intensity of the color
was assessed visually.
4. Conclusions
A convenient method for the preparation of novel anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones
is proposed based on the diazotization reaction followed by cyclization of the corresponding 1-
amino-9,10-dioxo-9,10-dihydroanthracene-2-carboxamides under acidic conditions at room
temperature. The outcomes of our study revealed that some of the synthesized compounds (namely
32–34 and 36) exhibit promising antistaphylococcal activity, which creates the prospect of their
further in-depth studies as effective antibacterial agents.
Author Contributions: V.Z.: the synthesis of the compounds, M.S.: interpretation of the results and
characterization of all the obtained compounds, writing of original draft. E.R.: the X-ray structure determination
and description. M.V.: discussion of the experimental data of chemical part. M.S., V.N.: conceptualization and
supervision of synthesis, P.S.: the investigation and interpretation of the antimicrobial activity data, K.G.:
investigation of antimicrobial activity, S.M.: conceptualization and supervision of biological studies. All authors
participated in review and editing, read and approved the manuscript.
Funding: This research was funded by the Ministry of Education and Science of Ukraine, the bilateral Ukraine-
Poland R&D project, agreement № M/42-2019 (Project number: 0119U101928)
Conflicts of Interest: The authors declare no conflict of interest.
References
1.
2.
3.
4.
Hutchings, M.; Truman, A.; Wilkinson, B. Antibiotics: Past, present and future. Curr. Opin. Microbiol. 2019,
13, 51, 72–80. doi:10.1016/j.mib.2019.10.008.
Frieri, M.; Kumar, K.; Boutin, A. Antibiotic resistance. J. Infect. Public Health. 2017, 10, 369–378.
doi:10.1016/j.jiph.2016.08.007.
Pristov, K.E.; Ghannoum, M.A. Resistance of Candida to azoles and echinocandins worldwide. Clin.
Microbiol. Infect. 2019, 25, 792–798. doi:10.1016/j.cmi.2019.03.028.
Tong, S.Y.; Davis, J.S.; Eichenberger, E.; Holland, T.L.; Fowler, V.G.J. Staphylococcus aureus infections:
Epidemiology, pathophysiology, clinical manifestations, and management. Clin. Microbiol. Rev. 2015, 28,
603–661. doi:10.1128/CMR.00134-14.
5.
6.
Wiggli, B.J.; Frei, R.; Laffer, R.; Tschudin Sutter, S.; Widmer, A.F. Survival from methicillin-sensitive
Staphylococcus aureus bloodstream infections over 20 years: A cohort of 1328 patients. Swiss Med. Wkly.
2017, 147, w14508. doi:10.4414/smw.2017.14508.
Szweda, P.; Schielmann, M.; Kotlowski, R.; Gorczyca, G.; Zalewska, M.; Milewski, S. Peptidoglycan
hydrolases-potential weapons against Staphylococcus aureus. Appl. Microbiol. Biotechnol. 2012, 96, 1157–1174.
doi:10.1007/s00253-012-4484-3.
7.
8.
9.
Grecka, K.; Kuś, P.M.; Okińczyc, P.; Worobo, R.W.; Walkusz, J.; Szweda, P. The anti-staphylococcal
potential of ethanolic polish propolis extracts. Molecules 2019, 24, 1732. doi:10.3390/molecules24091732.
Ansari, S.; Jha, R.K.; Mishra, S.K.; Tiwari, B.R.; Asaad, A.M. Recent advances in Staphylococcus aureus
infection: Focus on vaccine development. Infect. Drug Resist. 2019, 12, 1243. doi:10.2147/IDR.S175014.
Diekema, D.J.; Pfaller, M.A.; Shortridge, D.; Zervos, M.; Jones, R.N. Twenty-Year trends in antimicrobial
susceptibilities among Staphylococcus aureus from the SENTRY antimicrobial surveillance program. Open
Forum Infect. Dis. 2019, 6 (Suppl. 1), S47–S53. doi:10.1093/ofid/ofy270.
10. Kang, J.; Dietz, M.J.; Hughes, K.; Xing, M.; Li, B. Silver nanoparticles present high intracellular and
extracellular killing against Staphylococcus aureus. J. Antimicrob. Chemother. 2019, 74, 1578–1585.
doi:10.1093/jac/dkz053.
11. Mathur, H.; Field, D.; Rea, M.C.; Cotter, P.D.; Hil, C.; Ross, R.P. Fighting biofilms with lantibiotics and other
groups of bacteriocins. npj Biofilms Microbiomes 2018, 4, 9. doi:10.1038/s41522-018-0053-6.
12. Lehman, S.M.; Mearns, G.; Rankin, D.; Cole, R.A.; Smrekar, F.; Branston, S.D.; Morales, S. Design and
preclinical development of a phage product for the treatment of antibiotic-resistant Staphylococcus aureus
Infections. Viruses 2019, 11, 88. doi:10.3390/v11010088.

Molecules 2019, 24, 4581
19 of 20
13. Chauhan, D.; Hati, S.; Priyadarshini, R.; Sen, S. Transcriptome analysis predicts mode of action of
benzimidazole molecules against Staphylococcus aureus UAMS-1. Drug. Dev. Res. 2019, 80, 1–14.
doi:10.1002/ddr.21523.
14. Subedi, Y.P.; Alfindee, M.N.; Shrestha, J.P.; Chang, C.-W.T. Tuning the biological activity of cationic
anthraquinone analogues specifically toward Staphylococcus aureus. Eur. J. Med. Chem. 2018, 157, 683–690.
doi:10.1016/j.ejmech.2018.08.018.
15. Zvarych, V.I.; Stasevych, M.V.; Stanko, O.V.; Komarovskaya-Porokhnyavets, E.Z.; Poroikov, V.V.; Rudik,
A.V.; Lagunin, A.A.; Vovk, M.V.; Novikov, V.P. Computerized prediction, synthesis, and antimicrobial
activity of new amino-acid derivatives of 2-Chloro-N-(9,10-Dioxo-9,10-Dihydroanthracen-1-yl) acetamide.
Pharm. Chem. J. 2014, 48, 584–588. doi:10.1007/s11094-014-1154-z.
16. Stasevych, M.; Zvarych, V.; Lunin, V.; Halenova, T.; Savchuk, O.; Dudchak, O., Vovk, M.; Novikov, V.
Novel anthraquinone-based derivatives as potent inhibitors for receptor tyrosine kinases. Indian J. Pharm.
Sci. 2015, 77, 634–637. doi:10.4103/0250-474X.169062.
17. Stasevych, M.; Zvarych, V.; Lunin, V.; Kopak, N.; Komarovska-Porokhnyavets, O.; Deniz, N.G.; Sayil, C.;
Ozyurek, M.; Guclu, K.; Vovk, M.; et al. Synthesis, investigation of antimicrobial and antioxidant activity of
anthraquinonylhydrazones. Monatsh. Chem. 2018, 149, 1111–1119. doi:10.1007/s00706-018-2157-3.
18. Kumar, R.; Singh, A.D.; Singh, J.; Singh, H.; Roy, R.K.; Chaudhary, A. 1,2,3-Triazine scaffold as a potent
biologically active moiety:
A
mini review. Mini Rev. Med. Chem. 2014, 14, 72–83.
doi:10.2174/1389557513666140103111017.
19. Kumar, R.; Kumar, N.; Roy, R.K.; Singh, A. Triazines—A comprehensive review of their synthesis and
diverse biological importance. Curr. Med. Drug Res. 2017, 1, 173.
20. Kumar, K.S.; Adepu, R.; Sandra, S.; Rambabu, D.; Krishna, G.R.; Reddy, C.M.; Misra, P.; Pal, M.; Cu-
mediated N-arylation of 1,2,3-triazin-4-ones: Synthesis of fused triazinone derivatives as potential
inhibitors of chorismate mutase. Bioorganic. Med. Chem. Lett. 2012, 22, 1146–1150.
doi:10.1016/j.bmcl.2011.11.096.
21. Cascioferro, S.; Parrino, B.; Spanò, V.; Carbone, A.; Montalbano, A.; Barraja, P.; Diana, P.; Cirrincione, G.
Synthesis and antitumor activities of 1,2,3-triazines and their benzo- and heterofused derivatives. Eur. J.
Med. Chem. 2017, 142, 74–86. doi:10.1016/j.ejmech.2017.06.003.
22. Hamama, W.S.; El-Bana, G.G.; Shaaban, S.; Habib, O.M.O.; Zoorob, H.H. Advances in the domain of 4-
amino-3-mercapto-1,2,4-triazine-5-ones. RSC Adv. 2016, 6, 24010–24049. doi:10.1039/C5RA26433B.
23. Kumar, R.; Singh, A.D.; Singh, J.; Singh, H.; Roy, R.K.; Chaudhary, A. 1,2,3-Triazine Scaffold as a potent
biologically active moiety:
A
mini review. Mini Rev. Med. Chem. 2014, 14, 72–83.
doi:10.2174/1389557513666140103111017.
24. Khalid, Z.; Ahmad, H.A.; Munawar, M.A.; Khan, M.; Gul, S. 1,2,3-Benzotriazin-4(3H)-ones: Synthesis,
reactions and applications. Heterocycles 2017, 94, 3–54. doi:10.3987/REV-16-846.
25. Stasevych, M.; Zvarych, V.; Lunin, V.; Deniz, N.G.; Gokmen, Z.; Akgun, O.; Ulukaya, E.; Poroikov, V.;
Gloriozova, T.; Novikov, V. Computer-aided prediction and cytotoxicity evaluation of some
dithiocarbamates of 9,10-anthracenedione as new anticancer agents. SAR QSAR Environ. Res. 2017, 28, 355–
366. doi:10.1080/1062936X.2017.1323796.
26. Stasevych, M.V.; Zvarych, V.I.; Lunin, V.V.; Khomyak, S.V.; Vovk, M.V.; Novikov, V.P. Synthesis of
pyrazole and tetrazole derivatives of 9,10-anthraquinonylhydrazones. Chem. Heterocycl. Compd. 2017, 53,
942–944. doi:10.1007/s10593-017-2148-z.
27. Stasevych, M.V.; Zvarych, V.I.; Stan’ko, O.V.; Vovk, M.V.; Novikov, V.P. Synthesis of 2-(N-benzoylimino)-
N-(9,10-dioxo-9,10-dihydroanthracen-1-yl) thiazoles. Chem. Heterocycl. Compd. 2014, 49, 1831–1833.
doi:10.1007/s10593-014-1437-z.
28. Zvarych, V.I.; Stasevych, M.V.; Stan’ko, O.V.; Musyanovych, R.Y.; Novikov, V.P. Amino acid derivatives
of 2-chloro-N-(9,10-dioxy-9,10-dihydroanthracen-1-yl) acetamide. Rus. J. Org. Chem. 2014, 50, 306–307.
doi:10.1134/S1070428014020316.
29. Zvarych, V.I.; Stasevych, M.V.; Lunin, V.V.; Vovk, M.V.; Novikov, V.P. Synthesis of 9,10-Anthracenedione
Diethyldithiocarbamates Rus. J. Gen. Chem. 2016, 86, 2699–2701. doi:10.1134/S1070363216120227.
30. Stasevych, M.; Zvarych, V.; Musyanovych, R.; Novikov, V.; Vovk, M. Synthesis of N-benzoyl-N’-(9,10-
dioxo-9,10-dihydroanthracene-1-yl)-thioureas and quantum-chemical analysis of the reaction passing.
Chem. Chem. Technol. 2014, 8, 135–140. doi:10.23939/chcht08.02.135.

Molecules 2019, 24, 4581
20 of 20
31. Rubin, J.E.; Ball, K.R.; Chirino-Trejo, M. Antimicrobial susceptibility of Staphylococcus aureus and
Staphylococcus pseudintermedius isolated from various animals. Can. Vet. J. 2011, 52, 153–157.
32. Atshan, S.S.; Nor Shamsudin, M.; Lung, L.T.; Sekawi, Z.; Pei Pei, C.; Karunanidhi, A.; Jeevajothi Nathan, J.;
Mateg Ali, A.; Ghaznavi-Rad, E.; Abduljaleel, S.A.; et al. Genotypically different clones of Staphylococcus
aureus are diverse in the antimicrobial susceptibility patterns and biofilm formations. Biomed Res. Int. 2013,
2013, 515712. doi:10.1155/2013/515712.
33. Bondock, S.; Rabie, R.; Etman, H.A.; Fadda, A.A. Synthesis and antimicrobial activity of some new
heterocycles incorporating antipyrine moiety. Eur J. Med. Chem. 2008, 43, 2122–2129.
doi:10.1016/j.ejmech.2007.12.009.
34. Saravanan, J.; Mohan, S.; Roy, J.J. Synthesis of some 3-substituted amino-4,5-tetramethylene thieno[2,3-d] [
1,2,3]-triazin-4 (3H)-ones as potential antimicrobial agents. Eur J. Med. Chem. 2010, 45, 4365–4369.
doi:10.1016/j.ejmech.2010.05.061.
35. El-Gohary, N.S.; Hawas, S.S.; Gabr, M.T.; Shaaban, M.I.; El-Ashmawy, M.B. New series of fused
pyrazolopyridines: Synthesis, molecular modeling, antimicrobial, antiquorum-sensing and antitumor
activities. Bioorganic Chem. 2019, 92, 103109. doi:10.1016/j.bioorg.2019.103109.
36. Liu, H.; Long, S.; Rakesh, K.P.; Zha, G.F. Structure-activity relationships (SAR) of triazine derivatives:
Promising antimicrobial agents. Eur. J. Med. Chem. 2019, 23, 111804. doi:10.1016/j.ejmech.2019.111804.
37. Gebreyohannes, G.; Nyerere, A.; Bii, C.; Sbhatu, D.B. Challenges of intervention, treatment, and antibiotic
resistance of biofilm-forming microorganisms. Heliyon. 2019, 5, e02192. doi:10.1016/j.heliyon.2019.e02192.
38. Sheldrick, G., A short history of SHELX. Acta Crystallogr. Section A Found. Crystallogr. 2008, 64, 112–122.
doi:10.1107/S0108767307043930.
39. Armarego, W.L.F.; Chai, C. Purification of Laboratory Chemicals, 5th ed.; Elsevier: Oxford, UK, 2003.
40. Hargreaves, T.; Eyles, H.G.; Peters, A.T. New intermediates and dyes. Part XI. Novel nucleophilic
substitution and group elimination in the 2-carbamoylanthraquinone series. J. Chem. Soc. C Org. 1968, 19,
2431–2435. doi:10.1039/J39680002431.
41. Samoilova, A.A.; Gladkova, V.V. Compatibility of bicomponent mixtures of disperse dyes. Tekstil’naya
Promyshlennost (Moscow, Russian Federation). 1981, 8, 57–59.
42. Clinical Laboratory Standard Institute. Performance Standards for Antimicrobial Susceptibility Testing;
Seventeenth Informational Supplement; CLSI document M100–S17; CLSI: Wayne, PA, USA, 2007.
43. Rex, J.H. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard—
Third Edition; Clinical & Laboratory Standards Institute: Wayne, PA, USA, 2008; CLSI Document M27-A3.
44. Walencka, E.; Sadowska, B.; Rozalska, S.; Hryniewicz, W.; Rozalska, B. Lysostaphin as a potential
therapeutic agent for staphylococcal biofilm eradication. Pol. J. Microbiol. 2005, 54, 191–200.
45. Kairo, S.K.; Bedwell, J.; Tyler, P.C.; Carter, A.; Corbel, M.J. Development of a tetrazolium salt assay for
rapid determination of viability of BCG vaccines. Vaccine 1999, 17, 2423–2428.
Sample Availability: Samples of the compounds 5–38 are available from the authors.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).